1.	Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258AIC02, 2011-001725-24, NCT01478373
2.	Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2010-535, NCT01484041
3.	TKI258 in Castrate Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2008-0510, NCT00831792
4.	TKI258 for Metastatic Inflammatory Breast Cancer Patients Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0296, NCT01262027
5.	TKI 258 in Von Hippel-Lindau Syndrome (VHL) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0650, NCT01266070
6.	A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2211, 2011-000266-35, NCT01379534
7.	Dovitinib in Adenoid Cystic Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H-1012-047-344, NCT01417143
8.	Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST) Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: AMC1101, NCT01440959
9.	Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 15627, NCT01524692
10.	Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2210, 2011-001230-42, NCT01528345
11.	A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A1201, NCT01576380
12.	Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCDCC#231, CTKI258AUS21T, NCT01676714
13.	A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OCOG-2012-DOVE, NCT01678105
14.	Dovitinib for Gastric Cancer With FGFR2 Amplification Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AMC1202, NCT01719549
15.	Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU12-157, NCT01732107
16.	Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: KCSG-GU11-05, GU11-05, NCT01741116
17.	Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CASE4312, NCI-2012-02284, NCT01753713
18.	A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: OCOG-2012-DOVE-M, NCT01769547
19.	Dovitinib in Neuroendocrine Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 23811, NCT01635907
20.	1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CTKI258AAU02T, ACTRN12612000140853, NCT01791387
21.	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258AUS26, NCT01831726
22.	Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2124, 2011-000103-41, NCT01443481
23.	Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11-0946, NCT01496534
24.	Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors or Advanced Pancreatic Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: I 175610, NCI-2010-02034, NCT01497392
25.	Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: CNIO-BR-01-2011, NCT01548924